ChAracterization of Patients and Treatment OUtcomes in Severe Tricuspid Regurgitation

Launched by MEDICAL UNIVERSITY OF WARSAW · Feb 16, 2025

Keywords

ClinConnect Summary

This clinical trial is studying patients with severe tricuspid regurgitation, a condition where the heart's tricuspid valve doesn't close properly, leading to heart failure and other issues. The goal is to gather information about patients who might benefit from a specific treatment called transcatheter tricuspid valve intervention (TTVI). Researchers want to learn more about the types of patients who qualify for this procedure, the reasons some patients may not be eligible, and how effective and safe TTVI is in both the short and long term.

To be eligible for this study, patients must have tricuspid regurgitation and qualify for the TTVI procedure. However, those who qualify for other types of surgical treatments for their heart condition cannot participate. If someone joins the study, they will go through a standard qualification process and will be monitored over time with check-ups, heart imaging tests, and lab work to see how well the treatment works and if it has any side effects. This trial is currently recruiting participants, and it welcomes individuals of all genders aged 65 and older.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • tricuspid regurgitation
• • qualification for transcatheter tricuspid valve intervention
• Exclusion Criteria:
• • tricuspid regurgitation qualified for surgical treatment
• • concomitant left heart valve disease qualified for surgical treatment
• • multivessel coronary artery disease qualified for coronary artery bypass grafting
• • lack of patient's consent to enter the registry